GEN Exclusives

More »

GEN News Highlights

More »
Feb 27, 2014

La Jolla Licenses GW Technology for HRS Compound

  • La Jolla Pharmaceutical said today it signed an option agreement to license from George Washington University (GW) an unspecified technology to be used in developing the company’s second lead product.

    The technology will be applied in La Jolla’s development of LJPC-501, a natural peptide antagonist of the renin-angiotensin pathway.

    LJPC-501 is designed for treatment of hepatorenal syndrome (HRS), a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.

    Last year the FDA accepted La Jolla’s IND to study LJPC-501 in HRS patients. At the time, the company spoke of launching a Phase I clinical trial for the experimental drug during 2013. But that study (NCT01906307) was not yet open for participant recruitment as of the trial’s most recent update on Oct. 7, according to

    La Jolla said the agreement with GW will also add potential proprietary protection to La Jolla’s pipeline, which includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.

    La Jolla’s lead product is GCS-100, a first-in-class inhibitor of galectin-3, a molecular target linked to chronic organ failure and cancer. The company also has a third product candidate in development, LJPC-401, a natural peptide for the treatment of iron overload.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »